Available online: Associated Data This section collects any data citations, data availability statements, or supplementary materials included in this article
All prescriptions are issued by licensed medical providers and incorporated into a physician-guided weight loss program following telemedicine regulations
A pooled analysis of the STEP 1-3 clinical trials found nausea affected roughly 44% of participants on semaglutide 2.4 mg, with most GI symptoms mild to moderate and concentrated in the first weeks of treatment
These meds are often less expensive than semaglutide, and a 2025 trial published in the New England Journal of Medicine that compared both medications found that tirzepatide was more effective for weight losshelping participants drop up to 25% of their body weight over the course of the 72-week study
[DOI] [PubMed] [Google Scholar] 3.Harding J.L., Pavkov M.E., Magliano D.J., Shaw J.E., Gregg E.W